Table 3.

Plasma Opg and Rankl concentrations in wild-type (Lgals3^+/+), heterozygous (Lgals3^KO/+), and mutant (Lgals3^KO/KO) mice^a

	Females		Males
Variables compared	24 wk	36 wk	24 wk	36 wk
Opg/(pg·mL-1)
Wild type	2 662.7 ± 213.0	2 552.5 ± 155.2	2 320.6 ± 137.1	2 751.5 ± 293.8
Heterozygote	2 388.1 ± 189.5	2 216.4 ± 246.1	2 215.3 ± 180.1	2 153.9 ± 198.0*
Mutant	2 320.2 ± 70.9	2 205.6 ± 166.5	1 744.9 ± 87.4*	1 900.9 ± 89.9**
Rankl/(pg·mL-1)
Wild type	153.4 ± 12.4	152.1 ± 14.3	161.7 ± 16.6	188.4 ± 17.5
Heterozygote	151.7 ± 10.9	175.4 ± 20.7	140.5 ± 8.1	169.9 ± 9.7
Mutant	145.8 ± 10.1	188.9 ± 14.9	124.5 ± 3.9	174.9 ± 7.9
Opg/Rankl
Wild type	17.9 ± 1.7	17.9 ± 2.5	15.2 ± 1.5	14.7 ± 1.1
Heterozygote	16.4 ± 1.9	13.2 ± 1.6*	16.3 ± 2.2	13.0 ± 1.6
Mutant	16.4 ± 1.3	12.3 ± 1.2*	14.0 ± 0.6	11.1 ± 0.9

Opg, osteoprotegerin; Rankl, receptor activator of nuclear kappa B ligand.

^aValues are expressed as mean ± S.E.M. (n = 6–10); Holm–Sidak post-hoc analysis adjusted P-values compared to wild type; bold values highlight *P < 0.05, **P < 0.01.